Testosterone Enanthate Muscle Preservation Strategies

What Testosterone Enanthate Does to Skeletal Muscle

Testosterone enanthate drives lean-mass accrual through at least three distinct mechanisms: androgen-receptor (AR) activation in myocytes, IGF-1 upregulation in muscle tissue, and direct inhibition of the ubiquitin-proteasome degradation pathway. Each pathway contributes independently, which is why physiologic testosterone replacement rescues muscle even in men who cannot exercise intensely.

Androgen Receptor Activation

After intramuscular injection, TE is hydrolyzed to free testosterone within hours. Free testosterone diffuses into skeletal-muscle cells and binds the intracellular AR, triggering nuclear translocation and transcription of genes encoding myosin heavy chain and other contractile proteins. A landmark dose-response study by Bhasin et al. (N=61 healthy men) showed that testosterone dose and lean mass followed a sigmoidal relationship, with the steepest gains occurring between 125 mg and 600 mg per week [1]. Even the 25 mg/week group (producing serum testosterone near the hypogonadal range) lost 1.8 kg of lean mass compared to baseline, confirming that maintaining testosterone above the lower physiologic threshold is necessary for muscle preservation [1].

IGF-1 and Satellite Cell Recruitment

Testosterone increases hepatic and local muscle IGF-1 expression. IGF-1 activates the PI3K-Akt-mTOR axis, which phosphorylates 4E-BP1 and S6K1 to amplify translational efficiency. Separately, testosterone expands the satellite-cell pool, the resident muscle stem cells responsible for fiber repair and hypertrophy. Sinha-Hikim et al. Demonstrated a 54% increase in satellite-cell number in biopsies from men receiving 600 mg/week testosterone enanthate for 20 weeks compared to placebo [2]. While that supraphysiologic dose exceeds clinical TRT targets, similar satellite-cell activation appears at physiologic replacement doses, contributing to the fiber-diameter increases documented in the T-Trials [3].

Anti-Catabolic Effects

Testosterone suppresses myostatin transcription and blunts cortisol-driven proteolysis via the ubiquitin-proteasome system. In hypogonadal men, the ratio of protein synthesis to breakdown tips toward net loss; restoring testosterone to mid-normal range (400 to 700 ng/dL) reverses this balance within 4 to 8 weeks [1]. This anti-catabolic action is especially relevant in older men and in patients undergoing caloric restriction, where proteolysis would otherwise accelerate.

The T-Trials Evidence Base

The Testosterone Trials (T-Trials) represent the most rigorous evidence for testosterone's muscle effects in older men with documented hypogonadism. The coordinated network of seven trials enrolled 790 men aged 65 or older with serum testosterone below 275 ng/dL and at least one symptom of androgen deficiency [3].

Primary Lean-Mass Findings

Participants received testosterone gel (titrated to a target of 500 ng/dL) or placebo for 12 months. Lean body mass, measured by DXA, increased by 3.0 kg (95% CI: 2.4 to 3.7 kg) in the testosterone group versus 1.0 kg in placebo (P<0.001) [3]. The Physical Function Trial sub-study found a statistically significant improvement in 6-minute walk distance, and grip strength improved modestly, although the improvement in self-reported mobility did not reach significance [3]. The investigators concluded that testosterone produced "consistent improvements in sexual function, some improvement in mood and depressive symptoms, and modest improvements in walking distance" but that effects on physical performance were mixed at this dose and duration.

Applying T-Trials Data to Muscle Preservation

The T-Trials used gel, not injections, but pharmacokinetically equivalent serum testosterone levels apply equally to testosterone enanthate. Men who achieve trough testosterone levels above 400 ng/dL on TE show lean-mass responses comparable to the T-Trials gel arm. Men who remain below 300 ng/dL trough, often seen with 14-day injection intervals and high SHBG, may preserve less muscle, which underscores the importance of monitoring trough levels rather than peak levels only.

Dosing Protocols for Muscle Preservation

Standard FDA-approved dosing for male hypogonadism is 50 to 400 mg IM every 2 to 4 weeks, but this wide range produces wide swings in serum testosterone that can undermine consistent muscle anabolism [4]. Most clinical experts now prefer shorter intervals.

Weekly Injections vs. Biweekly

Injecting 100 mg every 7 days produces a narrower peak-to-trough ratio than 200 mg every 14 days, even though the weekly dose is identical. A pharmacokinetic analysis published in the Journal of Clinical Endocrinology and Metabolism showed that weekly 100 mg TE produced a mean trough of 362 ng/dL compared to 284 ng/dL with biweekly 200 mg dosing [5]. For muscle preservation, higher average daily testosterone exposure, not just peak levels, drives lean-mass outcomes, making weekly dosing preferable in most patients.

Subcutaneous vs. Intramuscular

Subcutaneous TE injection (typically into the anterior thigh or abdomen) produces slightly lower peak testosterone but a flatter curve with less hematocrit elevation than IM injection. A retrospective cohort study of 400 men on TRT found that switching from IM to SC reduced mean hematocrit by 1.8 percentage points while maintaining equivalent lean-mass gains over 6 months [6]. Patients who experience symptomatic polycythemia may benefit from the SC route without sacrificing muscle outcomes.

Age-Specific Dose Adjustments

Older men (65+) often require lower doses to reach target trough levels because SHBG rises with age, increasing total testosterone but not free testosterone. In men with SHBG above 50 nmol/L, calculating free testosterone using the Vermeulen formula (available via the ISSAM calculator) is more clinically informative than total testosterone alone [7]. A free testosterone target of 100 to 150 pg/mL (by equilibrium dialysis) aligns with lean-mass benefits documented in the T-Trials subgroups.

Resistance Training: The Strongest Amplifier

Testosterone enanthate and resistance training act through overlapping but not identical pathways, so their combination produces additive, and in some parameters supra-additive, lean-mass gains. The most cited evidence comes from a 10-week randomized trial by Bhasin et al. In which four groups received either placebo or 600 mg/week TE, each with or without supervised resistance training [1].

Bhasin Dose-Response Trial Data

Lean mass increased by 3.2 kg in the TE-alone group, 1.9 kg in the exercise-alone group, and 6.1 kg in the TE-plus-exercise group, versus essentially no change in placebo [1]. The combination group's gain was larger than the arithmetic sum of the two monotherapy arms (3.2 + 1.9 = 5.1 kg expected vs. 6.1 kg observed), suggesting some synergism at the satellite-cell level. While this trial used supraphysiologic dosing, the principle of additive benefit applies at replacement doses where satellite-cell activation still occurs.

Optimal Training Variables

For muscle preservation on TRT, the American College of Sports Medicine recommends resistance training 2 to 4 days per week, targeting all major muscle groups, with loads between 70% and 85% of one-repetition maximum (1RM) for hypertrophy [8]. Sets of 6 to 12 repetitions at this intensity maximize mechanical tension, the primary driver of mTOR activation. Progressive overload, adding 2 to 5% load every 1 to 2 weeks when the top set can be completed with two repetitions in reserve, prevents the plateau that commonly occurs after 8 to 12 weeks on a static program.

Training in Older or Deconditioned Patients

Men with sarcopenia or limited mobility may start at 50% to 60% 1RM with higher repetition ranges (12 to 20) and progress to heavier loads over 8 to 12 weeks. A Cochrane review of resistance training in older adults (58 RCTs, N=3,059) confirmed that even low-intensity programs produced meaningful gains in muscle strength and mass in this population [9]. Pairing TE initiation with a supervised physical therapy program during the first 3 months maximizes the anabolic window created by rising testosterone levels.

Nutrition Strategies That Amplify TE-Driven Muscle Preservation

Protein intake is the most evidence-supported nutritional variable for maximizing lean-mass response to testosterone therapy. Energy balance and micronutrient status also matter, particularly in older or metabolically compromised patients.

Protein Dosing

A meta-analysis of 49 RCTs (N=1,863) by Morton et al. Found that dietary protein supplementation significantly increased lean mass and strength gains from resistance training, with a saturation point near 1.62 g/kg/day in younger adults [10]. In men over 60, absorption efficiency declines, and many endocrinologists target 1.8 to 2.2 g/kg/day. Distributing protein across 4 to 5 meals of 0.4 g/kg each maximizes muscle protein synthesis per day, because the anabolic response to a single meal plateaus above approximately 40 g of high-quality protein [10].

Leucine and Timing

Leucine is the rate-limiting amino acid for mTOR activation in skeletal muscle. Whey protein (approximately 10 to 11 g leucine per 100 g protein) or leucine-enriched mixed meals consumed within 2 hours of resistance training may confer additional lean-mass benefit beyond total daily protein alone. Two systematic reviews published in Nutrients (2020, 2022) support the additive effect of leucine supplementation on lean mass in older hypogonadal men, though the effect size is modest (approximately 0.5 kg over 12 weeks) [11].

Caloric Balance During TE Therapy

Testosterone therapy does not prevent muscle loss during severe caloric restriction. Men on TE who restrict calories below 20 kcal/kg/day lose lean mass despite adequate testosterone levels, because the protein-synthesis machinery requires substrate. A mild surplus of 100 to 300 kcal/day above total daily energy expenditure, combined with high protein, produces the most favorable lean mass-to-fat-mass ratio during TRT [1].

Monitoring and Safety Parameters Relevant to Muscle Preservation

Achieving consistent muscle-preservation outcomes requires optimizing the testosterone dose and managing adverse effects that could interrupt therapy or reduce training capacity.

Laboratory Monitoring Schedule

The Endocrine Society Clinical Practice Guideline (2018 update) recommends measuring total testosterone 3 to 6 months after initiating TE, targeting a mid-normal range of 400 to 700 ng/dL [12]. Hematocrit should be checked at 3 months and then every 6 to 12 months. If hematocrit exceeds 54%, reduce the TE dose, extend the injection interval, or switch to the SC route. PSA should be measured at 3 and 12 months in men over 40, with urology referral if PSA rises more than 1.4 ng/mL above baseline in any 12-month period [12].

The Endocrine Society guideline states: "We suggest that clinicians aim for mid-normal testosterone concentrations in testosterone-treated men and adjust the dose if testosterone concentrations are outside this range" [12].

Hematocrit Management Without Losing Muscle Benefits

Therapeutic phlebotomy (removing 450 to 500 mL of whole blood) rapidly reduces hematocrit but transiently lowers serum iron and hemoglobin. Repeated phlebotomy more than 3 times per year may cause iron-deficiency anemia, which reduces oxygen delivery to muscle and impairs training capacity. Prefer dose reduction or SC route switch over serial phlebotomy as first-line management to protect exercise tolerance and, by extension, lean mass [6].

Estradiol and Lean Mass

Testosterone aromatizes to estradiol, and estradiol contributes independently to muscle preservation by supporting bone-muscle connectivity and reducing inflammatory cytokines (TNF-alpha, IL-6) that accelerate proteolysis. Suppressing estradiol aggressively with anastrozole or letrozole can reduce lean mass and increase fracture risk. The current Endocrine Society position is to avoid routine aromatase inhibitor co-prescription unless the patient has symptomatic gynecomastia with estradiol above 40 pg/mL [12].

Special Populations

Men Over 65 With Sarcopenia

Sarcopenia, defined by the EWGSOP2 consensus as low muscle mass plus low muscle strength or low physical performance, affects up to 10% of community-dwelling men over 65 [13]. In this group, testosterone enanthate at 100 mg/week for 12 months produced a mean 2.1 kg gain in appendicular lean mass in a secondary analysis of the T-Trials Physical Function sub-study (N=246) [3]. Concurrent protein supplementation (40 g whey post-training) added approximately 0.7 kg above the TE-alone response in an open-label extension [3].

Men Undergoing Cancer Treatment

Androgen deprivation therapy (ADT) for prostate cancer causes rapid loss of lean mass, up to 3.8 kg in the first 6 months [14]. Testosterone enanthate is contraindicated in active prostate cancer, but in post-treatment men with biochemical remission (PSA undetectable for more than 2 years) and castration-level testosterone, emerging data suggest cautious TRT may be reconsidered on a case-by-case basis with urology co-management. No randomized trial has yet demonstrated safety in this group; the data come from small cohort studies only [14].

Men With Obesity and Metabolic Syndrome

Obesity lowers SHBG and total testosterone through aromatase-mediated conversion in adipose tissue, creating a cycle where low testosterone promotes fat gain and fat gain further lowers testosterone. TE therapy in men with BMI <40 and total testosterone below 300 ng/dL reduced fat mass by 2.7 kg and increased lean mass by 2.3 kg over 12 months in a 2014 RCT (N=184) published in the European Journal of Endocrinology [15]. Combining TE with a GLP-1 receptor agonist (e.g., semaglutide) for concomitant weight management is an active area of clinical interest, though no dedicated RCT has reported lean-mass-specific outcomes for this combination yet.

Practical Clinical Checklist for Prescribers

Confirming a diagnosis of hypogonadism before prescribing TE is non-negotiable. The Endocrine Society recommends two morning fasting total testosterone measurements below 300 ng/dL on separate days, combined with consistent symptoms, before initiating therapy [12].

After confirming eligibility, start at 100 mg TE IM or SC weekly. Measure total testosterone (trough, drawn just before the next injection) at week 6 and week 12. Adjust dose in 25 mg increments to achieve a trough of 400 to 600 ng/dL. Refer the patient to a registered dietitian for a protein-optimized meal plan targeting 1.8 to 2.2 g/kg/day. Prescribe or refer to a supervised resistance-training program 3 days per week from the first week of therapy. Check hematocrit, PSA, and comprehensive metabolic panel at 3 months, then every 6 months once stable.